<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prevention of parvovirus B19 infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prevention of parvovirus B19 infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prevention of parvovirus B19 infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne A Jordan, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angela M Caliendo, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human parvovirus B19 infections are common. They are usually mild or asymptomatic, and do not require treatment. In some cases, however, infection is associated with sufficiently severe complications that treatment is indicated and may be lifesaving.</p><p>The major clinical manifestations that can occur with parvovirus B19 infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Erythema infectiosum</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis or arthralgia</p><p class="bulletIndent1"><span class="glyph">●</span>Transient aplastic crisis</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal hydrops</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic infection with or without anemia</p><p></p><p>The major issues related to the treatment of symptomatic parvovirus B19 infection and to prevention of infection will be reviewed here. The epidemiology, transmission, clinical syndromes, diagnosis, and management of parvovirus B19 infection in pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/8274.html" rel="external">"Virology, epidemiology, and pathogenesis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Management of parvovirus B19 infection is primarily symptomatic and varies with the clinical manifestation (<a class="graphic graphic_table graphicRef50679" href="/z/d/graphic/50679.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p>There is no specific antiviral drug available for the treatment of parvovirus B19 infection. In vitro studies that demonstrate inhibition of parvovirus B19 replication with <a class="drug drug_general" data-topicid="131802" href="/z/d/drug information/131802.html" rel="external">brincidofovir</a> (a lipid conjugated form of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>) at a concentration achievable in vivo, with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, or with a coumarin derivative, warrant further evaluation [<a href="#rid2">2-6</a>]. Another in vitro study in CD36+ cells demonstrated that flavonoids, which are known to have antiviral properties, inhibited the endonuclease activity of the B19 NS1 protein and thus B19 deoxyribonucleic acid (DNA) replication [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H3"><span class="h2">Erythema infectiosum</span><span class="headingEndMark"> — </span>Erythema infectiosum ("fifth" disease) is a self-limited, mild illness most often occurring in children. There is no specific therapy and usually no indication for symptomatic treatment. In some patients, symptomatic therapy for arthralgias, arthritis, or pruritus may be indicated [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Arthritis or arthralgia</span><span class="headingEndMark"> — </span>Arthritis or arthralgia are most often reported in adult females but can occur in either sex and at any age. The joint symptoms usually last one to two weeks, but can persist for weeks, months, and even years [<a href="#rid9">9</a>]. </p><p>Nonsteroidal anti-inflammatory drugs can provide symptomatic relief. Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) has been given to two patients with presumed chronic parvovirus B19 infection and chronic arthritis [<a href="#rid10">10</a>]. The arthritis was not cured, but there may have been a short-term decrease in symptoms. These limited data do not support the use of IVIG treatment for parvovirus B19-associated arthropathy.</p><p class="headingAnchor" id="H5"><span class="h2">Transient aplastic crisis</span><span class="headingEndMark"> — </span>Acute parvovirus B19 is a cause of transient aplastic crisis (TAC) in patients with certain underlying hematologic abnormalities, in which the interruption of red cell production in this setting rapidly leads to a severe anemia. </p><p>The anemia is often sufficiently severe (hemoglobin levels below 6 g/dL with few or no reticulocytes) to require transfusion until the patient's immune response eliminates the infection and red cell production returns. As an example, in a series of 62 sickle cell patients with TAC, 54 (87 percent) required blood transfusions, 39 (63 percent) were hospitalized, and one (1.6 percent) died [<a href="#rid11">11</a>]. The one death illustrates the importance of prompt diagnosis and treatment with transfusion therapy if indicated by the patient's condition.</p><p>The usual course of parvovirus associated-anemia is spontaneous resolution within a few days to weeks. Beyond supportive red blood cell transfusion, more aggressive therapy with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is generally limited to patients with chronic parvovirus B19 infection and chronic anemia (see below).</p><p class="headingAnchor" id="H6"><span class="h2">Chronic infection</span><span class="headingEndMark"> — </span>Chronic infection also can occur, producing anemia or other signs or symptoms.</p><p class="headingAnchor" id="H7"><span class="h3">Chronic infection with anemia</span><span class="headingEndMark"> — </span>Most patients with chronic parvovirus B19 infection and anemia have received immunosuppressive therapy for cancer, leukemia, or tissue transplantation, have a congenital immunodeficiency, or have human immunodeficiency virus (HIV)-associated immunodeficiency. Reports of pure red cell aplasia have occurred in patients with HIV who have advanced immunosuppression [<a href="#rid12">12,13</a>]. Most of these reports have occurred prior to the availability of potent antiretroviral therapy (ART). (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Chronic infection in immunosuppressed hosts'</a>.)</p><p>In the setting of chronic infection with anemia in immunosuppressed patients, including those with HIV, we suggest <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> with reduction of immunosuppression if possible. This is consistent with guidelines from the American Society of Transplantation for the treatment of symptomatic parvovirus B19 infection in solid organ transplant recipients [<a href="#rid14">14</a>]. In persons with HIV, ART should be initiated or maintained.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with solid organ transplant or other non-HIV causes of immunosuppression, we suggest 400 mg/kg/day of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> for five consecutive days, along with reducing immunosuppressive therapy, if possible [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For persons with HIV, several different dosing regimens have been described, and the optimal one is unknown. Reported IVIG regimens include 1 g/kg/day for 2 days or 0.4 g/kg/day for 5 to 10 days [<a href="#rid12">12,13,15</a>]. One patient with HIV, chronic parvovirus B19 infection, and anemia apparently responded to treatment with 5 mL of intramuscular <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid16">16</a>]. We agree with other authors who suggest maintenance IVIG at doses of 0.4 g/kg/day every four weeks following the initial IVIG treatment dose to prevent relapse in patients with low CD4 cell counts (eg, &lt;100 cells/microL) [<a href="#rid13">13</a>].</p><p></p><p>Recurrence of anemia and reappearance or increases in parvovirus B19 DNA in serum have usually responded to additional courses of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> treatment. Furthermore, if the immunodeficiency improves (eg, after discontinuation of immunosuppressive therapy or with the initiation of ART for HIV), chronic infection and anemia may resolve spontaneously [<a href="#rid17">17-19</a>].</p><p>Support for <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in these populations comes mainly from retrospective studies. In a retrospective study of 10 patients with pure red cell aplasia and proven parvovirus B19 infection who were treated with IVIG, anemia resolved in 9 of 10 within a mean of 80 days [<a href="#rid20">20</a>]. Patients received a mean of 2.7 IVIG courses at an average dose of 1.3 ± 0.5 g/kg per course. The only patient who did not respond to IVIG had underlying myelodysplasia. Among the seven patients with available follow-up blood parvovirus B19 polymerase chain reaction (PCR) results, five had negative PCR results within a mean of 97 days (range 35 to 159 days). None of the 9 responders had a relapse during 12 months of follow-up. In a review of published studies that was part of the same report, hemoglobin level was corrected after the first IVIG course in 124 of 133 patients (93 percent) with pure red cell aplasia caused by parvovirus B19 infection, but disease relapsed in 42 (34 percent) at a mean of 4.3 months.</p><p>For patients with refractory anemia despite <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a> may be an option. In a study of kidney transplant recipients with refractory anemia despite IVIG therapy and with good allograft function (estimated glomerular filtration rate &gt;45mL/minute), foscarnet 6 g/day for 5 to 14 consecutive days successfully treated 91 percent of patients (10 out of 11) without any recurrence [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H8"><span class="h3">Chronic infection without anemia</span><span class="headingEndMark"> — </span>Chronic parvovirus B19 infection has been demonstrated in patients without anemia or underlying immunodeficiency [<a href="#rid22">22-25</a>]. It is not clear if <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> treatment is helpful in this setting. One such patient with thrombocytopenia received IVIG without an obvious response [<a href="#rid23">23</a>], while two patients with presumed chronic infection and arthritis had no virologic but possibly a transient clinical response [<a href="#rid10">10</a>]. In comparison, three patients with systemic vasculitis had an apparent clinical and virologic response after IVIG therapy [<a href="#rid22">22</a>]. Further study is needed to determine the role of IVIG in these patients.</p><p class="headingAnchor" id="H92115240"><span class="h2">Fetal infection</span><span class="headingEndMark"> — </span>The management of fetal anemia and hydrops secondary to parvovirus B19 infection is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy", section on 'Management of anemia and hydrops'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The best measures currently available to prevent parvovirus B19 infection are those designed to interrupt transmission by personal infection control practices, such as good hand hygiene, covering the face when sneezing or coughing, not touching the eyes, mouth, or nose, avoiding close contact with sick individuals, and remaining home when ill. Immunoprophylactic therapy has been considered in some instances, but insufficient data are available to determine if it is efficacious.</p><p class="headingAnchor" id="H13"><span class="h2">Preventing transmission</span><span class="headingEndMark"> — </span>Attention to good infection control practices should reduce the risk of transmitting parvovirus B19. Studies of rhinoviruses and enteroviruses, which are also spread by person-to-person contact, fomites, and large droplet aerosol, and are stable in the environment, suggest that hand washing and not sharing food or drinks is likely to prevent, at least partially, spread of parvovirus B19 in a variety of settings. One report of parvovirus B19 infections in a hospital suggested that good hygienic practices by staff may have decreased their risk of acquiring infection [<a href="#rid26">26</a>]. Staff who reported washing their hands rarely or only occasionally after contact with patients had a higher infection rate (p = 0.07).</p><p>The United States Centers for Disease Control and Prevention (CDC) recommends that patients with TAC be placed on standard and droplet isolation precautions for seven days and that immunodeficient patients with chronic infection be placed on droplet precautions for the duration of their hospitalization [<a href="#rid27">27</a>]. In comparison, patients with normal immune systems are probably not infectious after the onset of parvovirus B19-associated rash, arthralgias, or arthritis, when a robust antibody response would take place and dramatically reduce the patient's viral load.</p><p>Modes of transmission are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8274.html" rel="external">"Virology, epidemiology, and pathogenesis of parvovirus B19 infection", section on 'Transmission and risk factors for infection'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Groups or persons that might benefit from infection control measures</span><span class="headingEndMark"> — </span>Good infection control practices in the home, workplace, and hospital should be emphasized to decrease the risk of transmission to persons with compromised immune systems, those with a need for increased production of red cells (eg, sickle cell disease [SCD]), and pregnant women.</p><p>The possibility of fetal hydrops and death has generated considerable concern, especially during community outbreaks of parvovirus B19. As noted above, there is no specific prevention available. Frequently, during parvovirus B19 outbreaks, supervisors, health care workers, pregnant women, and others will ask whether avoiding the workplace or outbreak settings such as schools or child care centers will decrease the risk to the fetus. The CDC recommends that pregnant women be informed about the risks of infection and make their own decision after consultation with health care workers, public health officials, and family members [<a href="#rid28">28</a>].</p><p>Understanding the risk is essential to making this decision. The primary risk is fetal death, and this risk is given by the following equation [<a href="#rid28">28</a>]:</p><div class="formulaContainer"><div class="formula"><p>Rate of fetal death = (rate of susceptibility x rate of infection from the exposure) ÷ (rate of fetal death with infection)</p></div></div><p>Estimates for each of these factors are available:</p><p class="bulletIndent1"><span class="glyph">●</span>For women in their childbearing years, between 40 and 60 percent, depending on the community and antibody detection assay used, will test positive for parvovirus B19 immunoglobulin (Ig)G antibodies and are presumably not susceptible to infection [<a href="#rid29">29,30</a>]. IgG antibodies against the VP1-unique region offer lifelong protection against parvovirus B19 reinfection [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of fetal death with maternal infection is less than 10 percent and probably between 2 and 5 percent [<a href="#rid28">28,32,33</a>].</p><p></p><p>If we assume the risk of fetal death with infection is between 2 and 5 percent and the rate of susceptibility is 50 percent, then the risk of fetal death associated with the following settings can be estimated:</p><p class="bulletIndent1"><span class="glyph">●</span>Between 0.5 percent and 1.25 percent for a household exposure, assuming a 50 percent infection rate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Between 0.2 and 0.5 percent from working in a school with an erythema infectiosum outbreak, assuming a 20 percent infection rate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Between 0.06 and 0.15 percent from living in a community with an erythema infectiosum outbreak, assuming a 6 percent infection rate</p><p></p><p>The available data suggest that parvovirus B19 uncommonly, if ever, causes congenital anomalies [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H11358390"><span class="h2">Candidate vaccines</span><span class="headingEndMark"> — </span>Studies of candidate vaccines against parvovirus B19 have been hindered by potential side effects. Further developments of an initially promising recombinant human parvovirus B19 vaccine [<a href="#rid35">35</a>] and a viral-like particle vaccine [<a href="#rid36">36</a>] were suspended because of vaccine-associated adverse events. The reactogenicity with the previous vaccine candidates was found to be related to insect cell contaminants from insect cells used to produce the virus-like particles (VLPs) and to the phospholipase A<sub>2</sub> activity from the VP1 protein in the VLPs. </p><p>Subsequent efforts in developing a parvovirus B19 vaccine candidate are focused on expressing VP1 and VP2 proteins in <em>Saccharomyces cerevisiae</em> to produce VLPs. The VP1-coding region contains a point mutation, which inactivates the phospholipase A2 activity [<a href="#rid37">37</a>]. One <em>S. cerevisiae</em>-derived parvovirus B19 vaccine containing both VP1 and VP2 capsid antigens and co-administered with the adjuvant MF59 appeared promising in a preclinical mouse model [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H100583014"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics". The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We<sup> </sup>encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83162.html" rel="external">"Patient education: Erythema infectiosum (fifth disease) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of treatment – </strong>Parvovirus B19 infections are common, usually mild or asymptomatic, and generally require no or only symptomatic therapy. However, some uncommon severe complications of infection may warrant specific treatment (<a class="graphic graphic_table graphicRef50679" href="/z/d/graphic/50679.html" rel="external">table 1</a>). There is no specific antiviral drug available for the treatment of parvovirus B19 infection. (See <a class="local">'Introduction'</a> above and <a class="local">'Erythema infectiosum'</a> above and <a class="local">'Arthritis or arthralgia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of transient aplastic crisis – </strong>Transient aplastic crisis can occur when parvovirus B19 infection occurs in patients with underlying hematologic abnormalities, such as sickle cell disease, thalassemia, and hereditary spherocytosis, and causes severe anemia. The anemia is typically severe enough to warrant red blood cell transfusion but usually resolves spontaneously within a few days to weeks. (See <a class="local">'Transient aplastic crisis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of chronic infection – </strong>For immunocompromised patients with chronic parvovirus B19 infection and anemia, we suggest intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), in addition to decreasing immunosuppression, if possible (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). It is unclear if IVIG is beneficial in the setting of chronic parvovirus B19 infection without anemia. (See <a class="local">'Chronic infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parvovirus B19 infection during pregnancy – </strong>The management of fetal anemia and hydrops is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy", section on 'Management of anemia and hydrops'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevention of parvovirus B19 infection depends on good infection control practices targeted towards the various modes of transmission. As parvovirus B19 is likely spread in the community through close contact (eg, person to person, through fomites, or through large droplets), adequate hand washing practices and not sharing food or drink is likely to help prevent spread of parvovirus B19 in a variety of settings. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Good hygiene and infection control practices should be emphasized for patients with compromised immune systems, those with underlying hematologic abnormalities, and pregnant women. Because of the risk of fetal death in the setting of maternal infection, pregnant women should understand the risk of infection during parvovirus B19 outbreaks or exposures. (See <a class="local">'Groups or persons that might benefit from infection control measures'</a> above and  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nosocomial transmission of parvovirus B19 can occur between patients and staff but can be difficult to distinguish from infection acquired in the community during outbreaks. Droplet precautions are indicated for seven days for patients with transient aplastic crisis and for the duration of the hospitalization for immunodeficient patients with chronic infection. (See <a class="local">'Preventing transmission'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.</a></li><li><a class="nounderline abstract_t">Hankins JS, Penkert RR, Lavoie P, et al. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med (Maywood) 2016; 241:749.</a></li><li><a class="nounderline abstract_t">Bonvicini F, Bua G, Conti I, et al. Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells. Biochem Pharmacol 2017; 136:32.</a></li><li><a class="nounderline abstract_t">Bua G, Conti I, Manaresi E, et al. Antiviral activity of brincidofovir on parvovirus B19. Antiviral Res 2019; 162:22.</a></li><li><a class="nounderline abstract_t">Manaresi E, Gallinella G. Advances in the Development of Antiviral Strategies against Parvovirus B19. Viruses 2019; 11.</a></li><li><a class="nounderline abstract_t">Conti I, Morigi R, Locatelli A, et al. Synthesis of 3-(Imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one Derivatives and Study of Their Antiviral Activity against Parvovirus B19. Molecules 2019; 24.</a></li><li><a class="nounderline abstract_t">Xu P, Ganaie SS, Wang X, et al. Endonuclease Activity Inhibition of the NS1 Protein of Parvovirus B19 as a Novel Target for Antiviral Drug Development. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 1990; 33:1297.</a></li><li><a class="nounderline abstract_t">Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.</a></li><li><a class="nounderline abstract_t">Saag KG, True CA, Naides SJ. Intravenous immunoglobulin treatment of chronic parvovirus B19 arthropathy. Arthritis Rheum 1993; 36(Suppl):S67.</a></li><li><a class="nounderline abstract_t">Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child 1987; 62:585.</a></li><li><a class="nounderline abstract_t">Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.</a></li><li><a class="nounderline abstract_t">Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS 2000; 14:7.</a></li><li><a class="nounderline abstract_t">Eid AJ, Ardura MI, AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13535.</a></li><li><a class="nounderline abstract_t">Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Am J Hematol 1999; 61:16.</a></li><li><a class="nounderline abstract_t">Naides SJ, Howard EJ, Swack NS, et al. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993; 168:101.</a></li><li><a class="nounderline abstract_t">Chen MY, Hung CC, Fang CT, Hsieh SM. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 2001; 32:1361.</a></li><li><a class="nounderline abstract_t">Ware AJ, Moore T. Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:E122.</a></li><li><a class="nounderline abstract_t">Arribas JR, Peña JM, Echevarría JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med 2000; 132:1011.</a></li><li><a class="nounderline abstract_t">Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56:968.</a></li><li><a class="nounderline abstract_t">Yu Y, Bao R, Lyu J, et al. Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration. Infect Drug Resist 2021; 14:2911.</a></li><li><a class="nounderline abstract_t">Finkel TH, Török TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343:1255.</a></li><li><a class="nounderline abstract_t">Oeda E, Shinohara K, Inoue H, Nomiyama J. Parvovirus B19 infection causing severe peripheral blood thrombocytopenia and persistent viremia. Am J Hematol 1994; 45:274.</a></li><li><a class="nounderline abstract_t">Kerr JR, Curran MD, Moore JE, et al. Persistent parvovirus B19 infection. Lancet 1995; 345:1118.</a></li><li><a class="nounderline abstract_t">Watanabe K, Otabe K, Shimizu N, et al. High-sensitivity virus and mycoplasma screening test reveals high prevalence of parvovirus B19 infection in human synovial tissues and bone marrow. Stem Cell Res Ther 2018; 9:80.</a></li><li><a class="nounderline abstract_t">Seng C, Watkins P, Morse D, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect 1994; 113:345.</a></li><li><a class="nounderline abstract_t">Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38:81.</a></li><li><a class="nounderline abstract_t">Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.</a></li><li><a class="nounderline abstract_t">Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151.</a></li><li><a class="nounderline abstract_t">Zuffi E, Manaresi E, Gallinella G, et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 2001; 14:151.</a></li><li><a class="nounderline abstract_t">Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166.</a></li><li><a class="nounderline abstract_t">Kerr JR, O'Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994; 163:65.</a></li><li class="breakAll">Adler SP, Koch WC. Human parvovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th Ed, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.867.</li><li><a class="nounderline abstract_t">Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675.</a></li><li><a class="nounderline abstract_t">Bernstein DI, El Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011; 29:7357.</a></li><li><a class="nounderline abstract_t">Chandramouli S, Medina-Selby A, Coit D, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine 2013; 31:3872.</a></li><li><a class="nounderline abstract_t">Penkert RR, Young NS, Surman SL, et al. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease. Vaccine 2017; 35:3615.</a></li></ol></div><div id="topicVersionRevision">Topic 8330 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762186" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Parvovirus B19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940953" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28377277" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529090" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiviral activity of brincidofovir on parvovirus B19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31323869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Advances in the Development of Antiviral Strategies against Parvovirus B19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30875983" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Synthesis of 3-(Imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one Derivatives and Study of Their Antiviral Activity against Parvovirus B19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530599" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endonuclease Activity Inhibition of the NS1 Protein of Parvovirus B19 as a Novel Target for Antiviral Drug Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2169746" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2541666" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical manifestations of human parvovirus B19 in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intravenous immunoglobulin treatment of chronic parvovirus B19 arthropathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3039926" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Parvovirus associated aplastic crisis in homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2173460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12240888" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Parvovirus B19-related anemia in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30973192" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331506" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515096" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303273" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264051" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858172" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243178" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34349526" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910276" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296807" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Parvovirus B19 infection causing severe peripheral blood thrombocytopenia and persistent viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715366" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Persistent parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587847" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High-sensitivity virus and mycoplasma screening test reveals high prevalence of parvovirus B19 infection in human synovial tissues and bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7925671" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Parvovirus B19 outbreak on an adult ward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789689" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536885" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risks associated with human parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2539583" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Human parvovirus B19 infections in women of childbearing age and within families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3339634" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The prevalence of antibody to human parvovirus B19 in England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398810" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2161263" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200772" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200772" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12599085" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21807052" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and immunogenicity of a candidate parvovirus B19 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827313" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Generation of a parvovirus B19 vaccine candidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554503" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
